Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial-Reference-Cited by-同舟云学术

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Published:2023-02 Issue:2 Volume:81 Page:145-155.e1
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Michael Mini,Groothoff Jaap W.,Shasha-Lavsky Hadas,Lieske John C.,Frishberg Yaacov,Simkova Eva,Sellier-Leclerc Anne-Laure,Devresse Arnaud,Guebre-Egziabher Fitsum,Bakkaloglu Sevcan A.,Mourani Chebl,Saqan Rola,Singer Richard,Willey Richard,Habtemariam Bahru,Gansner John M.,Bhan Ishir,McGregor Tracy,Magen Daniella

Publisher

Elsevier BV

Subject

Nephrology

Reference39 articles.

1. Primary hyperoxaluria;Cochat;N Engl J Med,2013

2. International registry for primary hyperoxaluria;Lieske;Am J Nephrol,2005

3. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type;Mandrile;Kidney Int,2014

4. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort;van der Hoeven;Nephrol Dial Transplant,2012

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney involvement in rare hereditary diseases;Terapevticheskii arkhiv;2024-07-07

2. Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial;Kidney International Reports;2024-07

3. Oxalate Metabolism: From Kidney Stones to Cardiovascular Disease;Mayo Clinic Proceedings;2024-07

4. Injectable long-acting formulations (ILAFs) and manufacturing techniques;Expert Opinion on Drug Delivery;2024-06-02

5. Diagnosis and management of primary hyperoxalurias: best practices;Pediatric Nephrology;2024-05-16